country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Referencia número: HY-187539S

Copy Link Print Information

IPR agonist-1

IPR agonist-1 is a prostaglandin-based IP receptor agonist. IPR agonist-1 binds to the IP receptor, forms hydrogen bonds with Tyr75-Ser168-Arg279, and undergoes π-π stacking with Tyr281, thereby triggering downstream signaling pathways. IPR agonist-1 inhibits ADP (Adenosine 5'-diphosphate) (HY-W010918)-induced platelet aggregation in rabbit platelet-rich plasma. IPR agonist-1 can be used in the research of pulmonary arterial hypertension.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS: 3085716-86-2
Fòrmula: C₂₅H₂₄D₃N₃O₃
Peso molecular:420.52

Almacenamiento:

Please store the product under the recommended conditions in the Certificate of Analysis.

IPR agonist-1 Chemical Structure

No. CAS: 3085716-86-2

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Protocolo (1)
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Ver todos los productos específicos de isoformas Prostaglandin Receptor :

In Vitro

IPR agonist-1 (7a-19) potently inhibits ADP-induced platelet aggregation in rabbit platelet-rich plasma with an IC₅₀ of 0.97 μM^[1].
IPR agonist-1 (7a-19) binds robustly to the prostanoid IP receptor, forming critical hydrogen-bonding and π-π stacking interactions that align with its potent agonist activity^[1].
IPR agonist-1 (4 h) shows exceptional metabolic stability in rat liver microsomes, with 96.7% of the parent compound remaining after 4 h of incubation and minimal M1 metabolite formation^[1].
IPR agonist-1 does not exert significant hERG potassium channel inhibition in stably transfected HEK293 cells, with an IC₅₀ of 143.1 μM^[1].
IPR agonist-1 is nonmutagenic in the Mini-Ames assay across multiple bacterial strains, with or without metabolic activation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Parmacokinetics

Species	Dose	Route	C₀	T_1/2	AUC_0-t	C_max	T_max	Bioavailability
Rat^[1]	1.0 mg/kg	i.v.	6.20 μg/mL	12.0 h	26.7 μg/mL·h	/	/	/
Rat^[1]	5.0 mg/kg	p.o.	/	10.5 h	63.1 μg/mL·h	2.29 μg/mL	3.0 h	47.3 %

In Vivo

IPR agonist-1 (7a-19) (1.0-5.0 mg/kg; i.v., p.o.; single dose) demonstrates extended in vivo half-life, enhanced systemic exposure, and high oral bioavailability in healthy Sprague-Dawley rats, with an 11-fold increase in intravenous systemic exposure and 47.3% oral bioavailability relative to the reference agent MRE-269^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (SD) rats^[1]
Dosage:

1.0 mg/kg (i.v.); 5.0 mg/kg (p.o.)
Administration:

i.v.; single dose; p.o.; single dose
Result:

Exhibited a terminal half-life of 12.0 h, an initial plasma concentration of 6.20 μg/mL, and a systemic exposure of 26.7 h·μg/mL after intravenous administration of 1.0 mg/kg.
Exhibited a terminal half-life of 10.5 h, a maximum plasma concentration of 2.29 μg/mL reached at 3.0 h, a systemic exposure of 63.1 h·μg/mL, and an oral bioavailability of 47.3% after oral administration of 5.0 mg/kg.

Chemical Information

No. CAS 3085716-86-2
Peso molecular 420.52
Fòrmula C₂₅H₂₄D₃N₃O₃
SMILES

[2H]C([2H])([2H])N([C@@H]1CC[C@H](OCC(O)=O)CC1)C2=NC(C3=CC=CC=C3)=C(C4=CC=CC=C4)N=C2
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocolo

All Signal Pathway Related

Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.

Pureza y Documentación

Instrucciones de manejo (2659 KB)

Referencias

[1]. Cai X, et al. Design, synthesis, and evaluation of diphenylpyrazinyl amino cycloalkoxy acetic acids as IP receptor agonists. ACS Med Chem Lett. 2026.

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtener un presupuesto En stock

Other size

Obtener un presupuesto